AMD1 (adenosylmethionine decarboxylase 1) is a cytosolic enzyme catalyzing the first committed step in polyamine biosynthesis 1. It converts S-adenosylmethionine to decarboxylated S-adenosylmethionine (dcSAM), enabling production of spermidine and spermine—essential metabolites for cell growth and proliferation 2. AMD1 is mechanistically regulated by mTORC1 signaling; mTORC1 activation stabilizes AMD1 protein, sustaining polyamine metabolism that promotes cancer cell oncogenicity 1. In breast cancer, AMD1 overexpression drives aggressiveness through a spermidine-eIF5A hypusination-TCF4 translational axis, with elevated AMD1 correlating with high grade, metastasis, and poor survival 3. Similarly, in gastric cancer and BRAF-mutant melanoma, AMD1 upregulation associates with tumor progression and therapeutic resistance 2, 4. AMD1 expression is elevated across multiple cancer types—prostate, breast, gastric, and lung cancers—where it promotes cell proliferation, migration, and survival while suppressing apoptosis 5. Genetic variants in AMD1 (rs1279590) correlate with improved overall survival in non-small cell lung cancer patients 6. Methionine availability regulates AMD1 expression, suggesting dietary modification as a potential therapeutic strategy 7. AMD1 represents a druggable metabolic target with prognostic and therapeutic significance across multiple malignancies.